Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Crispr Therapeutics AG (NASDAQ:) on Friday, setting a price target of $175, which is approximately 41.46% above the present share price of $123.71.
Livshits expects Crispr Therapeutics AG to post earnings per share (EPS) of -$1.51 for the second quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Moderate Buy rating of shares in Crispr Therapeutics AG, with an average price target of $148.29.
The analysts price targets range from a high of $189 to a low of $55.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $539 thousand and a net profit of -$114.54 million. The company's market cap is $9.37 billion.
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.